ABCL
AbCellera Biologics, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$11.93
+1.10%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$12.05
From 52W high−19.50%
Volume3.12M
Market cap$3.87B
P/E (TTM)—
P/S (TTM)58.4x
Div yield—
Key dataOct 19, 2026
Open
$12.05
From 52W high
−19.50%
Volume
3.12M
Market cap
$3.87B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−20.5x
P/E (TTM)
—
RSI (14)
45.7
MomentumView details →
1D Return
+1.10%
YTD Return
+249.71%
SummaryUpdated Jun 1, 2026
AbCellera Biologics Inc. (NASDAQ:ABCL) is a Canadian biotechnology company founded in 2012 and headquartered in Vancouver, Canada. The company went public in December 2020 during the height of the COVID-19 pandemic, largely driven by its successful collaboration with Eli Lilly to develop bebtelovimab, a COVID-19 antibody treatment. AbCellera has since transitioned from primarily being a platform and partnership company to becoming a clinical-stage biotechnology company focused on developing its own pipeline of antibody therapeutics while maintaining selective strategic partnerships.
Similar companies
Latest newsMore news →
AbCellera announced it will report its third quarter 2026 financial results on November 9, 2026.18d agoAbCellera Biologics shares surged 121% over three months amid positive ABCL635 data, major partnerships and a stronger financial position.27d agoAbCellera announced the presentation of Phase 2 data for ABCL635 at the IMS World Congress on Menopause 2026.33d ago